GRCE
Grace Therapeutics, Inc. · Healthcare
Insiders bought $567K of Grace Therapeutics, Inc. in the last 12 months
2 insiders bought on 6 days.
GRCE over the last year
Largest buyers, last 12 months
GRCE after insider buys
3 months after each buy, from the first price a copier could get.
No buys have 3 months of prices yet. A record shows here at 3.
Every filing
6 insider filings since 2026, newest first
Opaleye Management Inc. · 10% owner
Opaleye Management Inc. · 10% owner
Opaleye Management Inc. · 10% owner
Opaleye Management Inc. · 10% owner
Opaleye Management Inc. · 10% owner
Prashant Kohli · Chief Executive Officer
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.